Thymic epithelial neoplasm

Thymic epithelial neoplasms (TENs) are a group of rare tumors arising from the epithelial cells of the thymus, a small organ located in the anterior mediastinum (upper chest behind the breastbone) that plays a critical role in immune system development. This category encompasses both thymomas and thymic carcinomas. Thymomas are the more common subtype and tend to grow slowly, often remaining encapsulated, while thymic carcinomas are more aggressive, with a higher tendency to invade surrounding structures and metastasize. The World Health Organization classifies thymomas into types A, AB, B1, B2, and B3 based on the morphology of the epithelial cells and the proportion of immature T lymphocytes present. Many patients with thymic epithelial neoplasms are asymptomatic at diagnosis, with the tumor discovered incidentally on chest imaging. When symptoms occur, they may include chest pain, cough, shortness of breath, and superior vena cava syndrome (swelling of the face and upper body due to vascular compression). A hallmark feature of thymomas is their association with paraneoplastic autoimmune conditions, most notably myasthenia gravis, which occurs in approximately 30-50% of thymoma patients and causes muscle weakness and fatigue. Other associated autoimmune disorders include pure red cell aplasia, hypogammaglobulinemia (Good syndrome), and various autoimmune conditions affecting the skin, joints, and endocrine system. Treatment depends on the stage and histological type of the tumor. Complete surgical resection is the primary treatment and offers the best chance of cure for localized disease. For advanced or unresectable tumors, multimodal approaches including chemotherapy (often cisplatin-based regimens), radiation therapy, and targeted therapies may be employed. Thymic carcinomas generally carry a poorer prognosis than thymomas. Long-term follow-up is essential due to the risk of late recurrence, even many years after initial treatment. Associated autoimmune conditions require independent management and may persist even after tumor removal.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Thymic epithelial neoplasm